EU HE - MISSION CANCER | IMPACT-AML Master framework and pragmatic clinical trial for relapse or refractory acute myeloid leukemia
|
Programme |
Horizon Europe |
|
Call for proposal |
|
|
Funding scheme |
HORIZON-RIA |
|
Consortium |
17 participants (IRST as coordinator) |
|
Start date |
1st april 2023 |
|
Duration |
60 months |
In its role as coordinator of the IMPACT project, IRST holds a pivotal position. Notably, our Institute stands as one of the pioneering coordinators of a Cancer Mission under Horizon Europe in Italy. This significant involvement showcases how research remains a fundamental pursuit for our institute, particularly in addressing major shared challenges at the European level, such as cancer.
IMPACT proposes to create an inclusive master framework for relapsed or refractory acute myeloid leukemia (STREAM) to include patients with R/R AML across Europe, including neglected cohorts. This objective will be achieved by conducting a prospective randomized pragmatic clinical trial (RPCT). The consortium's efforts will deliver groundbreaking outcomes, surpassing the state of the art in R/R AML through a first-of-its-kind clinical trial. These substantial findings will provide essential data, benefiting national healthcare providers, policymakers, and health authorities by offering insights into optimized and affordable treatment.
This project not only underscores the commitment to addressing critical health concerns, but also highlights strong dedication to advancing groundbreaking solutions that will reshape the landscape of cancer research and treatment in Europe.
